Equities research analysts expect ReWalk Robotics Ltd (NASDAQ:RWLK) to post ($0.32) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for ReWalk Robotics’ earnings, with estimates ranging from ($0.35) to ($0.29). ReWalk Robotics posted earnings per share of ($0.52) in the same quarter last year, which would indicate a positive year over year growth rate of 38.5%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that ReWalk Robotics will report full year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.31) to ($1.17). For the next financial year, analysts forecast that the company will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.53) to ($1.27). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for ReWalk Robotics.

ReWalk Robotics (NASDAQ:RWLK) last issued its quarterly earnings results on Thursday, August 3rd. The medical device company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.06. The firm had revenue of $2.01 million for the quarter, compared to the consensus estimate of $1.71 million. ReWalk Robotics had a negative net margin of 389.13% and a negative return on equity of 528.26%. The company’s revenue for the quarter was up 145.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.64) EPS.

Several equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of ReWalk Robotics from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Oppenheimer Holdings, Inc. set a $4.00 price objective on shares of ReWalk Robotics and gave the stock a “buy” rating in a report on Friday, August 4th. Finally, Canaccord Genuity dropped their price objective on shares of ReWalk Robotics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

ReWalk Robotics (RWLK) opened at 1.65 on Friday. The stock has a 50 day moving average of $1.44 and a 200-day moving average of $1.62. The firm’s market cap is $35.88 million. ReWalk Robotics has a 12 month low of $1.10 and a 12 month high of $6.50.

In related news, Director Jeff Dykan sold 37,030 shares of the firm’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $3.00, for a total transaction of $111,090.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Scp Vitalife Partners (Israel) sold 9,271 shares of the firm’s stock in a transaction on Monday, June 26th. The stock was sold at an average price of $3.00, for a total transaction of $27,813.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 199,050 shares of company stock worth $604,020. 13.70% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in ReWalk Robotics stock. Renaissance Technologies LLC increased its stake in shares of ReWalk Robotics Ltd (NASDAQ:RWLK) by 61.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,600 shares of the medical device company’s stock after acquiring an additional 30,000 shares during the period. Renaissance Technologies LLC owned about 0.48% of ReWalk Robotics worth $165,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.27% of the company’s stock.

WARNING: “Zacks: Brokerages Expect ReWalk Robotics Ltd (RWLK) Will Post Earnings of -$0.32 Per Share” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/10/zacks-brokerages-expect-rewalk-robotics-ltd-rwlk-will-post-earnings-of-0-32-per-share.html.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.

Get a free copy of the Zacks research report on ReWalk Robotics (RWLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.